Pfizer and BioNTech have announced that their Covid-19 vaccine candidate, BNT162b2 (mRNA based), was found to be effective against Covid-19 in a Phase III study of patients with no evidence of prior infection with SARS-CoV-2.
Pfizer and BioNTech have announced that their Covid-19 vaccine candidate, BNT162b2 (mRNA based), was found to be effective against Covid-19 in a Phase III study of patients with no evidence of prior infection with SARS-CoV-2.